AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02968082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
Trial: NCT01764841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
Trial: NCT00746551
Drug: Ferli-6® (Continental Pharm co., ltd.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
Trial: NCT00746551
Drug: Venofer® (Vifor AG, St. Gallen, Switzerland)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
Trial: NCT03436121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
Trial: NCT02075541
Drug: NaCl Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Trial: NCT01134120
Drug: LY2784544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
Trial: NCT01579578
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg, oral dose twice daily
Trial: NCT01579578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral dose twice daily
Trial: NCT01302691
Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
RxNorm normalized name: hydrochlorothiazide / losartan potassium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
Trial: NCT01302691
Drug: Placebo to MK-0954E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet, containing placebo, orally, once daily, for 8 weeks.
Trial: NCT04169230
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration lactose placebo tablet
Trial: NCT01270971
Drug: AN2690 Topical Solution, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Trial: NCT01270971
Drug: Solution Vehicle
RxNorm normalized name: Flavor Sweet Oral Solution Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Trial: NCT02015663
Drug: Tobramycin Inhalation Powder
RxNorm normalized name: Tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
Trial: NCT00136916
Drug: Inhaled Insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Trial: NCT00386269
Drug: Codeine Phosphate Analgesia
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01030406
Drug: 40/0mg taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
Trial: NCT01030406
Drug: 80/0mg taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
Trial: NCT01030406
Drug: 40/240mg taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
Trial: NCT01030406
Drug: 80/480mg taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
Trial: NCT01030406
Drug: 0/0mg taken first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo All arms taken with a 48 hour washout between doses
Trial: NCT00136916
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Trial: NCT00006085
Drug: CP-609,754
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03790293
Drug: corticosteroids'therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
Trial: NCT00417196
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01458067
Drug: GSK2636771
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT01614535
Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
Trial: NCT00334854
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02822144
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00758446
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, p.o, daily, 14 days
Trial: NCT04232839
Drug: BI 894416 Formulation A2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
Trial: NCT00249834
Drug: Recombinant human chorionic gonadotrophin (r-hCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
Trial: NCT03768713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
Trial: NCT02187783
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
Trial: NCT03115034
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
Trial: NCT03115034
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
Trial: NCT00177034
Drug: Narrow Band UVB Treatment
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02579629
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
Trial: NCT00569985
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02548195
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
Trial: NCT00643448
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
Trial: NCT00643448
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
Trial: NCT00643448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
Trial: NCT01130272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral tablets twice daily.
Trial: NCT00304525
Drug: RAF265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
Trial: NCT01347645
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
Trial: NCT02112838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily by mouth, over the course of 24 weeks
Trial: NCT00201721
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
Trial: NCT01414374
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
Trial: NCT01414374
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
Trial: NCT01101906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally
Trial: NCT03556033
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks treatment with placebo capsules on top of insulin treatment
Trial: NCT00512525
Drug: Ghrelin and saline (as placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00883051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01284868
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03998982
Drug: Glycyrrhetinic Acid
RxNorm normalized name: Glycyrrhetinic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound glycyrrhizin tablets 75 mg three times per day, 1 month
Trial: NCT00269893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo soulution either bolus or infusion.
Trial: NCT03254485
Drug: IW-1973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03254485
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT00832182
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
Trial: NCT01115452
Drug: 5% Potassium nitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% potassium nitrate solution
Trial: NCT01115452
Drug: 2.5% Potassium nitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% potassium nitrate solution
Trial: NCT02941562
Drug: FOLFOX4 chemotherapy,preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks
Trial: NCT02941562
Drug: Concurrent chemotherapy of neo-adjuvant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 825mg/m2 twice daily 5 days/week
Trial: NCT00004817
Drug: phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02941562
Drug: FOLFOX4 chemotherapy,post-operative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks
Trial: NCT04820907
Drug: HCP1904-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04820907
Drug: RLD2001-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT02452047
Drug: Placebo to CMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to CMS IV infusion once every 12 hours
Trial: NCT00017641
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02242461
Drug: Rhodiola placebo capsules
RxNorm normalized name: RHODIOLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn starch
Trial: NCT02242461
Drug: Rhodiola Crenulata
RxNorm normalized name: RHODIOLA CRENULATA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola Crenulata
Trial: NCT00153062
Drug: Aggrenox placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00153062
Drug: Micardis placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02112032
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
Trial: NCT01550445
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
Trial: NCT04290936
Drug: Vemlidy® (Tenofovir Alafenamide; TAF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
Trial: NCT04290936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
Trial: NCT01715831
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
Trial: NCT00187408
Drug: Low Molecular Weight Heparin (dalteparin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01198405
Drug: Guideline-driven standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
Trial: NCT01786473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01748370
Drug: Placebo hypogonadal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01748370
Drug: Placebo eugonadal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02995993
Drug: Moss-aGal (recombinant human alpha-galactosidase A produced in moss)
RxNorm normalized name: Streptococcus agalactiae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
Trial: NCT02940405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo given as a tablet one hour before staring the root canal treatment
Trial: NCT03341767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-wax in gelatin capsule
Trial: NCT01346865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1tablet bid
Trial: NCT04200885
Drug: Dexketoprofen Trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
Trial: NCT01429090
Drug: Vagantin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
Trial: NCT01058447
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, 250 mg, single dose
Trial: NCT01459926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT04184401
Drug: Ascites replacement with albumin and hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined strategy for ascites replacement~* 30% of ascites: replacement with 5% albumin~* 40% of ascites: replacement with Hartmann's solution
Trial: NCT04184401
Drug: Ascites replacement with hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann's solution only strategy for ascites replacement~- 70% of ascites: replacement with Hartmann's solution
Trial: NCT00103454
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02018133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2 capsule daily
Trial: NCT01774981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02669875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
Trial: NCT02360046
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
Trial: NCT00596427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets: 3 tablets twice per day
Trial: NCT02360046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
Trial: NCT00599911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per oral, once daily for 6 weeks
Trial: NCT04366245
Drug: Standard of care for SARS-CoV-2 infection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for SARS-CoV-2 infection
Trial: NCT03588273
Drug: Amoxil 500 MG Oral Capsule
RxNorm normalized name: Amoxil 500 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01210638
Drug: Oxymorphone
RxNorm normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet